Neuro-Oncologic
4 cases on brain-tumor pharmacology — temozolomide duration, bevacizumab for recurrent glioblastoma, prophylactic anticonvulsants around craniotomy, and dexamethasone taper after radiosurgery — choose a case below to open its full multi-voice debate.
A patient with a strong response to standard six-cycle temozolomide wants to keep going. The trials that tested exactly that question say his instinct, however understandable, isn’t backed by the evidence.
A real, replicated finding: bevacizumab extends the time before a recurrent glioblastoma progresses again, without extending how long the patient lives. For a mother racing a deadline that has nothing to do with a tumor scan, the two aren’t the same question.
The recommendation against routine seizure prophylaxis in brain tumor patients is unusually strong. The recommendation about the days immediately around surgery itself is a separate, much weaker one — and this case turns entirely on which one actually applies.
Five weeks into a dexamethasone taper, new fatigue and nausea could mean the edema is returning — or that the adrenal glands stopped keeping up with the drug some time before anyone was watching for it. The two explanations point toward opposite next doses.